View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Angi Launches New “AI Helper” as it Celebrates 30 Years of Innovation

Angi Launches New “AI Helper” as it Celebrates 30 Years of Innovation DENVER, June 17, 2025 (GLOBE NEWSWIRE) -- Today, Angi—formerly known as Angie’s List—is introducing a new, “AI Helper” to its service request experience, as part of its continued effort to simplify how homeowners connect with top-quality service pros and meet demand for smarter, more intuitive home improvement solutions. This innovation coincides with Angi’s 30th anniversary, marking three decades of connecting homeowners with skilled pros and driving industry innovation. At the heart of this enhancement is an intellig...

 PRESS RELEASE

Ligand Announces 2025 Investor Day in New York City

Ligand Announces 2025 Investor Day in New York City JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 10 a.m. Eastern Time at the Harvard Club. The event will include presentations from Ligand’s senior management team highlighting the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast of the event will be accessible through Ligand’s Investor Relations website at . A detailed agenda, in...

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 95.190USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: June 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Merit Medical Acquires Biolife Delaware, L.L.C.

Merit Medical Acquires Biolife Delaware, L.L.C. Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acq...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 17, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Ligand Pharmaceuticals Inc: 2 directors

Two Directors at Ligand Pharmaceuticals Inc bought 11,010 shares at between 104.060USD and 105.201USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...

 PRESS RELEASE

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand’s senior management team and board of directors to commemorate several recent company milestones, including two value-creating transactions. “Ringing the Nasdaq Opening Bell marks an exciting milestone in our company’s history. Over the past few years, we have made significant prog...

 PRESS RELEASE

Angi to Participate in the 53nd Annual J.P. Morgan Global Technology, ...

Angi to Participate in the 53nd Annual J.P. Morgan Global Technology, Media and Communications Conference DENVER, May 08, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) will participate in the 53nd Annual J.P. Morgan Global Technology, Media and Communications Conference on Thursday, May 15, 2025. CEO Jeffrey Kip will present at 8:40 a.m. ET. Both a live audio webcast and replay of the presentation will be available to the public in the IR section of Angi’s website at . About Angi Inc. Angi (NASDAQ: ANGI) helps homeowners get home projects done well and helps home service pros grow ...

 PRESS RELEASE

Ligand Reports First Quarter 2025 Financial Results

Ligand Reports First Quarter 2025 Financial Results First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the thr...

 PRESS RELEASE

Angi Inc. Earnings Release and Letter to Shareholders Available on Com...

Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its first quarter financial results and a letter to shareholders from CEO Jeffrey Kip on the investor relations section of its website at . As announced previously, Angi Inc. will host a conference call to discuss the company’s first quarter results and to answer questions. The call will be held on Wednesday, May 7, 2025, at 8:30 a.m. ET. Jeffrey Kip, CEO and Andrew Russakoff, CFO will participate. The live audiocast and replay will...

 PRESS RELEASE

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-I...

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulator...

 PRESS RELEASE

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Ar...

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium ...

Esquire Financial Holdings Inc: 2 directors

A director at Esquire Financial Holdings Inc sold 13,000 shares at 84.088USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

 PRESS RELEASE

Ligand to Participate in May Investor Conferences

Ligand to Participate in May Investor Conferences JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual). Management will participate in a fireside chat on May 13, 2025 at 3:30 p.m. ET and be available for one-on-one meetings.RBC Capital Markets Global Healthcare Conference (New York). Management will participate in a fireside chat on May 20, 2025 at 2:05 p.m. ET and be available f...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 26, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year...

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter o...

 PRESS RELEASE

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch